Codexis, Inc. (NASDAQ:CDXS) insider John J. Nicols sold 14,259 shares of the stock in a transaction on Wednesday, August 15th. The shares were sold at an average price of $15.14, for a total value of $215,881.26. Following the transaction, the insider now directly owns 1,084,538 shares of the company’s stock, valued at $16,419,905.32. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Shares of NASDAQ:CDXS traded up $0.50 on Friday, reaching $15.10. 6,480 shares of the company traded hands, compared to its average volume of 359,850. Codexis, Inc. has a fifty-two week low of $5.10 and a fifty-two week high of $16.80. The company has a market capitalization of $802.68 million, a PE ratio of -28.90 and a beta of -1.79.

Codexis (NASDAQ:CDXS) last announced its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.06. Codexis had a negative return on equity of 61.93% and a negative net margin of 29.83%. The company had revenue of $13.54 million during the quarter, compared to the consensus estimate of $11.87 million. research analysts expect that Codexis, Inc. will post -0.27 earnings per share for the current fiscal year.

CDXS has been the subject of a number of research reports. BidaskClub lowered Codexis from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, June 13th. Zacks Investment Research upgraded Codexis from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a research report on Thursday. Cowen assumed coverage on Codexis in a research report on Tuesday, June 19th. They set an “outperform” rating and a $18.00 price objective for the company. Finally, Stephens assumed coverage on Codexis in a research report on Wednesday, May 16th. They set an “overweight” rating and a $16.00 price objective for the company. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Codexis currently has a consensus rating of “Buy” and an average price target of $14.60.

Large investors have recently made changes to their positions in the company. Marco Investment Management LLC acquired a new stake in shares of Codexis during the 1st quarter valued at $132,000. Citadel Advisors LLC acquired a new stake in shares of Codexis during the 1st quarter valued at $138,000. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Codexis in the second quarter valued at $146,000. Trexquant Investment LP purchased a new stake in shares of Codexis in the first quarter valued at $148,000. Finally, MetLife Investment Advisors LLC purchased a new stake in shares of Codexis in the fourth quarter valued at $179,000. Institutional investors own 67.26% of the company’s stock.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.

Further Reading: Asset Allocation Models, Which is Right For You?

Insider Buying and Selling by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.